Live feed/
Filings
/
SCHEDULE 13D/A
/
0001193125-26-365096
Stake: 19.99%
Shares: 1,889,403
CUSIP: 04746L203
Class: Common Stock, $0.0001 par value
Item 4 — Purpose of Transaction
Item 4 of the Schedule 13D is amended and supplemented as follows: On August 22, 2026, Sermonix notified the Reporting Persons that it will distribute Sermonix Pre-Funded Warrants exercisable for 2,352,932 shares of Common Stock to PXV II pursuant to a distribution of securities to owners of Sermonix's common stock. The distribution is expected to be effective on October 26, 2026. Pursuant to the terms of the Sermonix Pre-Funded Warrants, the pre-funded warrants that will be held by PXV II will not be exerciseable to the extent that such exercise would result in beneficial ownership in excess of 19.99% of the outstanding shares of Common Stock of the Issuer.
Cross-References
Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
3 13D/G filings on this issuer
2 other filings besides this one
Filer Track Record
34 filings by this filer
33 other filings in the data moat
Short Interest · settle 2026-09-30
DTC 1.00
19,166 shares short · -19.0% vs prior
Other 13D/G Filings on LeonaBio, Inc.
| Filed | Form | Filer | Stake | Shares | |
|---|
| 2026-08-31 |
SCHEDULE 13D |
Sermonix Pharmaceuticals, Inc. |
36.90% |
5,502,402 |
view → |
| 2022-07-01 |
SC |
PERCEPTIVE ADVISORS LLC |
— |
— |
view → |
Other Filings by PERCEPTIVE ADVISORS LLC
| Filed | Form | Issuer | Stake | Shares | |
|---|
| 2026-10-01 |
SCHEDULE 13D/A |
Kardigan, Inc. |
— |
8,254,144 |
view → |
| 2026-09-23 |
SCHEDULE 13G |
Nurix Therapeutics, Inc. |
— |
— |
view → |
| 2026-08-27 |
SCHEDULE 13D/A |
Immatics N.V. |
— |
11,418,016 |
view → |
| 2026-08-14 |
SCHEDULE 13D/A |
Nautilus Biotechnology, Inc. |
9.10% |
11,634,211 |
view → |
| 2026-08-14 |
SCHEDULE 13D/A |
Solid Biosciences Inc. |
11.20% |
12,046,579 |
view → |
| 2026-07-23 |
SCHEDULE 13G |
Freenome, Inc. |
— |
— |
view → |
| 2026-07-20 |
SCHEDULE 13G |
Research Alliance Corporation IV |
— |
— |
view → |
| 2026-06-25 |
SCHEDULE 13D |
Kardigan, Inc. KARD |
8.90% |
8,254,144 |
view → |
| 2026-01-26 |
SCHEDULE |
TRINITY BIOTECH PLC TRIB |
9.90% |
1,463,058,248 |
view → |
| 2026-01-02 |
SCHEDULE |
MeiraGTx Holdings plc MGTX |
12.90% |
10,441,562 |
view → |
| 2025-02-21 |
SCHEDULE |
Solid Biosciences Inc. SLDB |
15.60% |
11,934,679 |
view → |
| 2025-02-14 |
SCHEDULE |
TRINITY BIOTECH PLC TRIB |
20.90% |
85,800,000 |
view → |
| 2025-01-31 |
SCHEDULE |
Nautilus Biotechnology, Inc. NAUT |
10.00% |
12,594,211 |
view → |
| 2023-10-17 |
SC |
Cerevel Therapeutics Holdings, Inc. |
— |
— |
view → |
| 2023-06-06 |
SC |
SOLENO THERAPEUTICS INC SLNO |
— |
— |
view → |
| 2023-05-30 |
SC |
SOLENO THERAPEUTICS INC SLNO |
— |
— |
view → |
| 2023-05-25 |
SC |
SOLENO THERAPEUTICS INC SLNO |
— |
— |
view → |
| 2023-04-25 |
SC |
Cerevel Therapeutics Holdings, Inc. |
— |
— |
view → |
| 2022-12-06 |
SC |
Solid Biosciences Inc. SLDB |
— |
— |
view → |
| 2022-07-01 |
SC |
Athira Pharma, Inc. LONA |
— |
— |
view → |
Showing 20 of 33
Want this depth on every filing the moment it hits SEC EDGAR?
Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.
See pricing →